PRESS RELEASE published on 04/30/2025 at 07:30, 1 year 3 months ago Nicox Provides Full Year 2024 Financial Results Nicox reports €7.9 million revenue for 2024 with exceptional income of €13.7 million from VYZULTA transfer. Cash of €10.5 million and NCX 470 Phase 3 trial results expected in Q3 2025 Financial Results Revenue Nicox NCX 470 VYZULTA
PRESS RELEASE published on 04/30/2025 at 07:30, 1 year 3 months ago Nicox : Résultats financiers de l’année 2024 Nicox annonce résultats financiers 2024, incluant CA de 7,9M€, produits exceptionnels de 13,7M€ et trésorerie de 10,5M€. Études cliniques NCX 470 en cours Résultats Financiers Trésorerie Études Cliniques Nicox NCX 470
BRIEF published on 03/19/2025 at 07:35, 1 year 4 months ago Nicox Completes Final Visit for NCX 470 Phase 3b Whistler Glaucoma Trial Glaucoma Nicox Clinical Results NCX 470 Phase 3b Trial
BRIEF published on 03/19/2025 at 07:35, 1 year 4 months ago Nicox a terminé la dernière visite de l'essai de phase 3b NCX 470 sur le glaucome à Whistler Nicox Résultats Cliniques NCX 470 Glaucome Essai De Phase 3b
PRESS RELEASE published on 03/19/2025 at 07:30, 1 year 4 months ago Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Nicox completes final patient visits in Phase 3b Whistler Glaucoma Trial for NCX 470, with results expected May 2025. Denali trial in progress, results planned for Q3 2025 Clinical Development Nicox NCX 470 Phase 3b Glaucoma Trial
PRESS RELEASE published on 03/19/2025 at 07:30, 1 year 4 months ago Nicoxannonce que la visite finale du dernier patient a été effectuée dans l’étude de phase 3b Whistler sur le NCX 470 pour le glaucome Nicox annonce la fin de la visite du dernier patient dans l'étude de phase 3b Whistler sur le NCX 470 pour le glaucome. Résultats attendus en mai 2025 Étude Clinique Nicox NCX 470 Glaucome Phase 3b
BRIEF published on 01/28/2025 at 07:35, 1 year 6 months ago Nicox : Participation aux Grands Congrès en 2025 Investissement Ophtalmologie Congrès Nicox NCX 470
BRIEF published on 01/28/2025 at 07:35, 1 year 6 months ago Nicox: Participation in Major Congresses in 2025 Investment Ophthalmology Congress Nicox NCX 470
PRESS RELEASE published on 01/28/2025 at 07:30, 1 year 6 months ago Nicox : Présentation Scientifique et Participation aux Congrès du premier semestre 2025 Nicox annonce sa participation à des congrès internationaux en ophtalmologie et finance au premier semestre 2025, y compris l'AGS 2025 Congrès Annuel Finance Ophtalmologie Congrès Nicox AGS 2025
PRESS RELEASE published on 01/28/2025 at 07:30, 1 year 6 months ago Nicox Announces Scientific Presentation and Conference Attendance in H1 2025 Nicox to present at AGS 2025 Annual Meeting and attend key ophthalmology and financial conferences in H1 2025. Dr. Robert Fechtner to present NCX 470 analysis at AGS 2025 Conference Ophthalmology Nicox NCX 470 AGS 2025
Published on 08/10/2026 at 15:30, 3 hours 53 minutes ago Silver Spruce Resources, Inc. Announces New Chief Financial Officer
Published on 08/10/2026 at 15:25, 3 hours 58 minutes ago Gemdale Gold Intersects 5.19m at 14.01 g/t Au within 110m at 1.18 g/t Au at the Pontio Gold Project, Finland
Published on 08/10/2026 at 14:30, 4 hours 53 minutes ago NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Published on 08/10/2026 at 13:30, 5 hours 53 minutes ago Sterling Expands High-Grade Copper Mineralization East at MEPS Intersecting 203 Metres at 0.51% CuEq: Includes 16.25 Metres at 2.31% CuEq and 9.50 Metres at 2.34% CuEq within 445 Metres at 0.40% CuEq
Published on 08/10/2026 at 13:00, 6 hours 23 minutes ago Alaska Energy Metals Announces Drilling Program for the Mcbride Prospect, Angliers-Belleterre Project, Quebec, Canada
Published on 08/10/2026 at 19:00, 23 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 03 AOUT 2026 au 07 AOUT 2026
Published on 08/10/2026 at 18:29, 53 minutes ago Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 08/10/2026 at 17:50, 1 hour 33 minutes ago Disclosure according to Article 5(1)(b) of the EU Regulation No. 596/2014 and Article 2(3) of the Delegated EU Regulation No. 2016/1052 - 1st Interim Report
Published on 08/10/2026 at 17:38, 1 hour 45 minutes ago PATRIZIA delivers strong earnings growth with EUR 42.7m EBITDA (+46.6% y-o-y) in H1 2026
Published on 08/10/2026 at 17:11, 2 hours 12 minutes ago CORRECTION FROM SOURCE: North Peak Commences 2026 Drilling Campaign at Prospect Mountain, Eureka, Nevada
Published on 08/10/2026 at 18:00, 1 hour 23 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 1 hour 23 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 11:53, 7 hours 29 minutes ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
